Document is current
Any future updates will be listed below
-
Authors
Fernandes, Ricardo
Jabbarizadeh, Behnam https://orcid.org/0009-0005-0728-8574
Rajeh, Adnan
Hong, Megan M Y https://orcid.org/0000-0001-6179-122X
Baines, Kelly J. https://orcid.org/0000-0002-3299-8659
Ernst, Scott
Winquist, Eric
Ali, Anorin Shadi
Penny, Susanne https://orcid.org/0000-0002-0543-564X
Figueredo, Rene
Parvathy, Seema Nair https://orcid.org/0000-0001-6738-000X
Lenehan, John G.
Pinto, Devanand M.
Silverman, Michael S.
Maleki Vareki, Saman https://orcid.org/0000-0002-9615-7779
-
Funding
Funding for this research was provided by:
Lotte and John Hecht Memorial Foundation (1-MR_2022_4884)
Gouvernement du Canada | Canadian Institutes of Health Research (203745)
- License Information
-
More Information
Article History
Received: 22 July 2025
Accepted: 12 December 2025
First Online: 28 January 2026
Competing interests
: S.M.V., M.S.S., S.N.P. and B.J. are co-founders of LND Therapeutics Inc., which holds the rights to LND101. S.M.V. and M.S.S. report US Patent application no. 63/913,940 related to FMT donor screening. S.M.V. reports a grant from Microviable Therapeutics outside the submitted work as well as consulting fees from Kanvas Biosciences and FedBio. R.F. has the following disclosures: advisory board or honoraria: Merck, Ipsen, Eisai, EMD Serono, Astellas, Novartis, Janssen, Pfizer, Bristol Myers Squibb and Bayer; travel grant: Janssen. E.W. declares research grants from Lilly, Novartis and Merck; consulting fees from Bayer, Bristol Myers Squibb, Eisai, EMD, Serono, Merck and Roche; and honoraria from EMD Serono. E.W. also declares travel support from Eisai. M.S.S. has served on the advisory board of Ferring Pharmaceuticals. All other authors declare no conflicts of interest.
